touchPANEL DISCUSSION

The practicalities of PARP: Optimizing the use of PARP inhibitors for first-line maintenance treatment in ovarian cancer

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Gynaecological Oncology, Ovarian Cancer Watch Time: 42 mins

touchPANEL DISCUSSION The practicalities of PARP: Optimizing the use of PARP inhibitors for first-line maintenance treatment in ovarian cancer

Experts consider the practical aspects of using PARP inhibitors for first-line maintenance treatment in ovarian cancer.

Dr Domenica Lorusso

Catholic University of Sacred Heart, Rome, Italy

CHAIR

Panelists:
Dr Yvette Drew, Prof. Dr. med. Frederik Marmé
 
Video Chapters
Introduction

Dr Domenica Lorusso introduces the expert panel and provides an overview of the rationale for PARP inhibitors as first-line maintenance treatment in ovarian cancer.

view bio and disclosures
1/4 Next Chapter
 
Case study 1: Managing a patient with ovarian cancer and a BRCA mutation

The expert panel considers the treatment options and factors guiding clinical management decisions in a patient with advanced ovarian cancer and a BRCA mutation.

view bio and disclosures
2/4 Next Chapter
 
Case study 2: Managing a patient with HRD-positive ovarian cancer

The expert panel considers treatment options and factors guiding clinical management decisions in a patient with advanced ovarian cancer that is positive for homologous recombination deficiency (HRD).

view bio and disclosures
3/4 Next Chapter
 
Case study 3: Managing a patient with HRP ovarian cancer

The expert panel considers treatment options and factors guiding clinical management decisions in a patient with advanced ovarian cancer that is homologous recombination proficient (HRP).

view bio and disclosures
4/4 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

Through a series of case-based discussions, this expert panel explores some of the practical considerations for using PARP inhibitors as first-line maintenance treatment in ovarian cancer. Topics covered include how to select the most appropriate treatment for each patient and optimal management of patients receiving a PARP inhibitor.

Learning Objectives

After watching this activity, participants should be better able to:

  • Identify patients who may benefit from treatment with a PARP inhibitor in the first-line maintenance setting
  • Discuss approaches to selecting the most appropriate PARP inhibitor for each patient
  • Describe how to manage patients receiving PARP inhibitor therapy optimally
Faculty & Disclosures
Dr Domenica Lorusso

Catholic University of Sacred Heart, Rome, Italy

Dr Domenica Lorusso is Associate Professor of Obstetrics and Gynecology at the Catholic University of Sacred Heart, Rome, Italy. She is also responsible for Clinical Research at Fondazione Policlinico Gemelli IRCCS. Dr Lorusso is actively involved in preclinical and clinical research, and has authored over 200 papers in the field of gynaecological cancers. Her work has contributed to an improvement in the quality of care and a reduction of treatment toxicity in women with advanced gynaecological malignancies. read more

Dr Lorusso is an active member of the MITO (Multicenter Italian Trial in Ovarian Cancer) Group, chairing the Clinical Trials Committee and International Relationship Committee since 2004. Under her supervision, the MITO group has established a reputation for world-leading research underpinning new standards of care in gynaecological oncology. Dr Lorusso is also a member of ENGOT (European Society of Gynaecological Oncology) and GCIG (Gynecological Cancer InterGroup). She is currently a member of the GCIG Board of Directors, and chairs the Gynecological Cancer Academy, under the umbrella of ENGOT, to support the education and leadership of future opinion leaders based in Europe.

Dr Domenica Lorusso discloses: Advisory Board fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline and Merck Sharp & Dohme. Consultancy fees from PharmaMar. Research support to institute from Clovis, GlaxoSmithKline and Merck Sharp & Dohme.

Prof. Dr. med. Frederik Marmé

University Hospital of Mannheim, Mannheim, Germany

Prof. Dr. med. Frederik Marmé is Professor of Obstetrics and Gynecology for the Medical Faculty of Mannheim at the University of Heidelberg in Germany. He is also the Head of the Clinical Trials Unit at the Department of Gynaecologic Oncology of the University Hospital of Mannheim. read more

Prof. Dr. med. Marmé is actively involved in clinical research, having served as the principal investigator for over 35 studies and as a co-principal investigator on nearly 50 others since 2004. His research interests include translational research, predictive and prognostic biomarkers, molecular profiling and immunotherapies in breast and ovarian cancer. He has co-authored over 130 peer-reviewed journal articles.

He is an elected member of the German Breast Group (GBG) and the executive Board of the AGO-study group, and an AGO study group representative for the ENGOT early drug development group. He serves as a member of the faculty of ESMO (European Society of Medical Oncology) and as an associate editor of Cancer Investigation. He also belongs to several clinical and scientific societies, including ESMO, the German Society of Hematology & Oncology (DGHO), the European Society of Gynecologic Oncology (ESGO) and the German Society of Obstetrics and Gynecology (DGGG).

Prof. Dr. med. Frederik Marmé discloses: Honoraria/expenses from Amgen, AstraZeneca, Celgene, Clovis, Eisai, GenicHealth, Gilead/Immunomedics, GlaxoSmithKline/Tesaro, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Myriad Genetics, Novartis, Pfizer, PharmaMar, Roche and Seagen. Advisory board/consultancy fees from Amgen, AstraZeneca, Celgene, Clovis, Eisai, GenicHealth, Gilead/Immunomedics, GlaxoSmithKline/Tesaro, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Myriad Genetics, Novartis, Pfizer, PharmaMar, Roche and Seagen. Research funding from AGO Studiengruppe, AstraZeneca, Clovis, GBG, Gilead/Immunomedics, GlaxoSmithKline/Tesaro, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar and Roche.

Dr Yvette Drew

University of British Columbia, Vancouver, BC, Canada

Dr Yvette Drew is Associate Professor at the University of British Columbia and Consultant Medical Oncologist at the BC Cancer Agency in Vancouver, BC, Canada. read more

Dr Drew has played a key role in both the pre-clinical and clinical development of PARP inhibitors in ovarian cancer. Her research interests are focused on targeting DNA repair pathways as a treatment for cancer.

Dr Drew is Deputy Lead at the Newcastle Experimental Cancer Medicine Centre for early phase clinical trials delivery. She is also a member of the NCRI (National Cancer Research Institute) ovarian and endometrial clinical studies sub-groups and principal investigator on a number of ovarian and endometrial cancer trials.

Dr Yvette Drew discloses: Advisory board fees from AstraZeneca, Clovis and GlaxoSmithKline. Speaker fees from AstraZeneca, Clovis, GlaxoSmithKline and Merck. Fees for chairing meetings from AstraZeneca, Clovis and GlaxoSmithKline. Research support to institution from AstraZeneca, Clovis (including royalties) and Merck.

Downloads

View and download resources from this activity to support your learning and share with colleagues

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchPANEL DISCUSSION on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72